Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 activation, cellular signaling and pro-inflammatory responses-Reference-Cited by-同舟云学术

Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 activation, cellular signaling and pro-inflammatory responses

Published:2013-11 Issue:11 Volume:25 Page:2093-2105
ISSN:0898-6568
Container-title:Cellular Signalling
language:en
Short-container-title:Cellular Signalling

Author:

Abdulkhalek Samar,Szewczuk Myron R.

Funder

Natural Sciences and Engineering Research Council of Canada (NSERC)

R.S. McLaughlin Scholarship

Ontario Graduate Scholarship

Canadian Institutes of Health Research (CIHR) Doctoral Award: Frederick Banting and Charles Best Canada Graduate Scholarship

Publisher

Elsevier BV

Subject

Cell Biology

Reference70 articles.

1. Neu1 Sialidase and Matrix Metalloproteinase-9 Cross-talk Is Essential for Toll-like Receptor Activation and Cellular Signaling

2. G-protein coupled receptor agonists mediate Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of TOLL-like receptors and cellular signaling

3. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer

4. CD36 is a sensor of diacylglycerides

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuraminidase-1 (NEU1): Biological Roles and Therapeutic Relevance in Human Disease;Current Issues in Molecular Biology;2024-07-26

2. Neuraminidase 1 regulates the cellular state of microglia by modulating the sialylation of Trem2;2024-05-20

3. Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial–Mesenchymal Transition Metastatic Phenotype;Cells;2024-03-08

4. Smart Nanomedicine Targeting Endocytosis Mediated by Cancer Cell Surface Neuraminidase‐1;Advanced NanoBiomed Research;2023-11-08

5. Genetics of enzymatic dysfunctions in metabolic disorders and cancer;Frontiers in Oncology;2023-08-02